Roche announced the results from the first year of a phase III study (DIVA) investigating an intravenous injection of Bonviva/Boniva (ibandronate) with extended intervals between dosages, for the ...
Roche and GlaxoSmithKline have submitted a new drug application (NDA) with the US FDA for a novel, intermittent intravenous (IV) injection formulation of bisphosphonate Boniva (ibandronate sodium) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results